University of Connecticut School of Medicine, Farmington, CT, USA.
University of Connecticut Department of Dermatology, 21 South Road, Farmington, CT, 06032, USA.
Am J Clin Dermatol. 2022 Jan;23(1):61-67. doi: 10.1007/s40257-021-00646-z. Epub 2021 Dec 2.
Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults. Aside from reviewing the pathogenesis and clinical presentation, we present potential diagnostic steps (such as skin scraping, serologies, biopsy, and patch testing) and management options for DFR ranging from allergen avoidance to dupilumab interruption. It is hoped that this article will serve as a means for clinicians to familiarize themselves with DFR regarding the differential diagnosis, diagnostic tools, and treatment options associated with this phenomenon.
度普利尤单抗面部发红（DFR），或在使用度普利尤单抗时面部和颈部出现湿疹样皮疹，在最近的病例报告中已有观察到。据估计，DFR 影响了 4%至 43.8%的度普利尤单抗使用者，包括儿童和成人。除了回顾发病机制和临床表现外，我们还提出了 DFR 的潜在诊断步骤（如皮肤刮擦、血清学检查、活检和斑贴试验）和管理选择，从过敏原回避到度普利尤单抗中断。我们希望本文能够为临床医生提供一种方法，使其熟悉 DFR 的鉴别诊断、诊断工具和与该现象相关的治疗选择。
